Predicting VTE in multiple myeloma, azithromycin promotes relapse after HSCT, and dual antigen targeted NK cells in B cell malignancies
Blood Podcast
00:00
PRISM Score in Multiple Myeloma
The risk prediction tool called the PRISM score was effective in stratifying patients into low, intermediate, and high-risk groups. The total number of VTE events was low, especially in the external validation dataset. In multiple myeloma, abnormal metaphase cytogenetics are an indicator of aggressive biology and poor survival.
Transcript
Play full episode
